Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4
The Canadian Journal of Psychiatry · 2024
DOI: 10.1177/07067437241233965 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift The Canadian Journal of Psychiatry, 2024. Verfasst von François Therrien und 6 weiteren Autor:innen. Beteiligte Einrichtung: Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada. Hauptthemen laut MEDLINE: Major Depressive Disorder, Antidepressive Agents, Quinolones, Thiophenes. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Canada, Otsuka Pharmaceutical Development & Commercialization Inc., H. Lundbeck A/S.
Abstract (Originalsprache)
Objectives
To characterize the effects of adjunctive brexpiprazole on patient life engagement and depressive symptoms in patients with major depressive disorder (MDD) using patient-reported outcomes.
Methods
An 8-week, Phase 4, open-label, interventional study was conducted at 15 Canadian trial sites between April 2021 and May 2022. Adult outpatients with MDD (at least moderately severe) and inadequate response to 1–2 antidepressants continued their current antidepressant and received oral adjunctive brexpiprazole 0.5–2 mg/day. Co-primary endpoints were change from baseline to Week 8 in Inventory of Depressive Symptomatology Self-Report (IDS-SR) 10-item Life Engagement subscale score, and IDS-SR 30-item total score. Safety was assessed by standard variables.
Results
Of 122 enrolled patients, 120 (98.4%) were treated (mean [ SD] dose: 1.2 [0.4] mg/day) and analyzed, and 111 (91.0%) completed the study. Statistically significant least squares mean improvements to Week 8 were observed on IDS-SR 10 Life Engagement subscale score (baseline mean [ SD]: 16.1 [4.7]; change [95% confidence interval]: −8.11 [−9.34, −6.88]; p < 0.001) and IDS-SR total score (baseline mean [ SD]: 41.3 [9.8]; change [95% confidence interval]: −17.38 [−20.08, −14.68]; p < 0.001). Improvements were observed from Week 2, onwards. Treatment-emergent adverse events with incidence ≥5% were fatigue ( n = 13, 10.8%), headache ( n = 13, 10.8%), insomnia ( n = 12, 10.0%), nausea ( n = 9, 7.5%), tremor ( n = 8, 6.7%), and weight increase ( n = 7, 5.8%). Six patients (5.0%) discontinued due to adverse events. Mean ( SD) change in body weight from baseline to last visit was +1.9 (3.4) kg.
Conclusions
Using an exploratory patient-reported outcome measure, patients with MDD and inadequate response to antidepressants who received open-label adjunctive brexpiprazole showed early and clinically meaningful improvement in patient life engagement, which should be further assessed in a prospective randomized controlled trial. Patient-rated depressive symptoms (on the validated 30-item IDS-SR) also improved. Adjunctive brexpiprazole was well tolerated, and no new safety signals were observed. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04830215.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Otsuka Canada Pharmaceutical Inc., Saint-Laurent, Quebec, Canada.
- Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, New Jersey, USA.
- Chokka Center for Integrative Health, Edmonton, Alberta, Canada.
- Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
- Department of Family and Community Medicine, University of Toronto, Toronto, Ontario, Canada.
- Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences; Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.
ORCID-Profile: Jeffrey Habert, Zahinoor Ismail
Förderung
- Lundbeck Canada
- Otsuka Pharmaceutical Development & Commercialization Inc.
- H. Lundbeck A/S
- Otsuka Canada Pharmaceutical
Zitieren
APA
Therrien, F., Ward, C., Chokka, P., Habert, J., Ismail, Z., McIntyre, R. S., & MacKenzie, E. M. (2024). Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4. The Canadian Journal of Psychiatry. https://doi.org/10.1177/07067437241233965
Vancouver
Therrien F, Ward C, Chokka P, Habert J, Ismail Z, McIntyre RS, et al. Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4. The Canadian Journal of Psychiatry. 2024. doi:10.1177/07067437241233965
BibTeX
@article{Therrien2024,
author = {Therrien, François and Ward, Caroline and Chokka, Pratap and Habert, Jeffrey and Ismail, Zahinoor and McIntyre, Roger S and MacKenzie, Erin M},
title = {Adjunctive Brexpiprazole for Patient Life Engagement in Major Depressive Disorder: A Canadian, Phase 4, Open-Label, Interventional Study: Brexpiprazole d'appoint pour l'engagement dans la vie des patients souffrant de trouble dépressif majeur: une étude interventionnelle canadienne ouverte de phase 4},
journal = {The Canadian Journal of Psychiatry},
year = {2024},
doi = {10.1177/07067437241233965}
}
EUVIMED